Zhejiang Langhua Pharmaceutical Co., Ltd, is a comprehensive pharmaceutical company engaged in research and development, production, marketing and sourcing of pharmaceutical products. As the subsidiary of world leading drug discovery CRO company Viva bio-tech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply. Langhua is the leading manufacturer of Spironolactone, Olanzapine, Antivirus and fluoroquinolones in the world, offers our global customers the high-quality and competitive Generic APIs...
Langhua operates 3 R&D centers in Shanghai, Ningbo and Taizhou with over 13,000 M2 lab space and two hundred chemists. Over half of people in R&D have either PhD degree or Master degree, and have rich experience in new drug development and CMC filing. The leaders of each field have work experience in global pharmaceutical giants and experienced in APIs & Formulation process development, scale up, IND & NDA documentation and filing.
R&D Centers are equipped with high class lab equipment and analytical instruments, including NMR(Bruker-400 MHz), LC-MS(Agilent), TOF-MS (Agilent)...
Langhua operates 3 R&D centers in China (Shanghai, Ningbo and Taizhou), 1 Manufacturing Site in Taizhou, China, and BD /Sales Office across United State, Belgium and Hongkong.
With advanced process technology R&D centers, high GMP/EHS compliance site, State-of-the-art facilities, rich experience of drug substance, Langhua intends develop the CDMO capability of Drug Product, to establish a high level, integrated small molecule API & Formulation platform, offers our customers Reliable, Efficient, End to End CDMO services.
